SIRT5 Promotes Hepatocellular Carcinoma Progression by Regulating Mitochondrial Apoptosis
文献类型：期刊论文
| 作者 | Zhang, Rixin3; Wang, Chengye3; Tian, Yu2,3; Yao, Yifan3; Mao, Jiakai3; Wang, Haibo3; Li, Zhenghan3; Xu, Yakun3; Ye, Mingliang1; Wang, Liming3 |
| 刊名 | JOURNAL OF CANCER
 |
| 出版日期 | 2019 |
| 卷号 | 10期号:16页码:3871-3882 |
| 关键词 | SIRT5 HCC Cytochrome c Acetylation |
| ISSN号 | 1837-9664 |
| DOI | 10.7150/jca.31266 |
| 通讯作者 | Wang, Liming(wangbcc259@163.com) |
| 英文摘要 | SIRT5 belongs to a family of NAD(+)-dependent lysine deacetylases called sirtuins. Although accumulating evidence indicates SIRT5 upregulation in cancers, including liver cancer, the detailed roles and mechanisms remain to be revealed. Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related deaths among men worldwide, and finding effective targets for HCC treatment and prevention is urgently needed. In the present study, we confirmed that mitochondrial sirtuins, particularly SIRT5, are more highly expressed in HCC cell lines than in normal liver cell lines. Moreover, SIRT5 knockdown suppresses HCC cell proliferation and SIRT5 overexpression promotes HCC cell proliferation. Furthermore, we verified that SIRT5 knockdown increases HCC cell apoptosis via the mitochondrial pathway. By co-IP and western blotting, we illustrated that SIRT5 deacetylates cytochrome c thus regulating HCC cell apoptosis. Taken together, our findings suggest that SIRT5 may function as a prognostic factor and drug target for HCC treatment. |
| WOS关键词 | CANCER STATISTICS ; SIRTUINS ; DESUCCINYLATION ; METABOLISM ; PHYSIOLOGY ; REDUCTION ; PROTEINS |
| 资助项目 | National Natural Science Foundation of China[81272368] ; National Natural Science Foundation of China[81471755] ; Clinical Capability Construction Project for Liaoning Provincial Hospitals[LNCCC-B03-2014] |
| WOS研究方向 | Oncology |
| 语种 | 英语 |
| WOS记录号 | WOS:000471273000030 |
| 出版者 | IVYSPRING INT PUBL |
| 资助机构 | National Natural Science Foundation of China ; National Natural Science Foundation of China ; Clinical Capability Construction Project for Liaoning Provincial Hospitals ; Clinical Capability Construction Project for Liaoning Provincial Hospitals ; National Natural Science Foundation of China ; National Natural Science Foundation of China ; Clinical Capability Construction Project for Liaoning Provincial Hospitals ; Clinical Capability Construction Project for Liaoning Provincial Hospitals ; National Natural Science Foundation of China ; National Natural Science Foundation of China ; Clinical Capability Construction Project for Liaoning Provincial Hospitals ; Clinical Capability Construction Project for Liaoning Provincial Hospitals ; National Natural Science Foundation of China ; National Natural Science Foundation of China ; Clinical Capability Construction Project for Liaoning Provincial Hospitals ; Clinical Capability Construction Project for Liaoning Provincial Hospitals |
| 源URL | [http://cas-ir.dicp.ac.cn/handle/321008/176147]  |
| 专题 | 大连化学物理研究所_中国科学院大连化学物理研究所 |
| 通讯作者 | Wang, Liming |
| 作者单位 | 1.Chinese Acad Sci, Natl Chromatog Res & Anal Ctr, Dalian Inst Chem Phys, CAS Key Lab Separat Sci Analyt Chem, 457 Zhongshan Rd, Dalian 116023, Liaoning, Peoples R China 2.Dalian Med Univ, Dept Vasc Surg, Hosp 2, 467 Zhongshan Rd, Dalian 116023, Liaoning, Peoples R China 3.Dalian Med Univ, Dept Surg, Div Hepatobiliary & Pancreat Surg, Hosp 2, 467 Zhongshan Rd, Dalian 116023, Liaoning, Peoples R China |
| 推荐引用方式 GB/T 7714 | Zhang, Rixin,Wang, Chengye,Tian, Yu,et al. SIRT5 Promotes Hepatocellular Carcinoma Progression by Regulating Mitochondrial Apoptosis[J]. JOURNAL OF CANCER,2019,10(16):3871-3882. |
| APA | Zhang, Rixin.,Wang, Chengye.,Tian, Yu.,Yao, Yifan.,Mao, Jiakai.,...&Wang, Liming.(2019).SIRT5 Promotes Hepatocellular Carcinoma Progression by Regulating Mitochondrial Apoptosis.JOURNAL OF CANCER,10(16),3871-3882. |
| MLA | Zhang, Rixin,et al."SIRT5 Promotes Hepatocellular Carcinoma Progression by Regulating Mitochondrial Apoptosis".JOURNAL OF CANCER 10.16(2019):3871-3882. |
入库方式： OAI收割
来源：大连化学物理研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。